Oct. 16 Financial Quick Takes: Hong Kong IPO could value Ascentage at $876M; plus Principia, Rhythm, ProQR, dMed, Ionova and Amarna

Ascentage sets Hong Kong IPO terms
Ascentage Pharma Group International would raise HK$404.4 million ($51.6 million) and be valued at HK$6.9 billion ($876.4 million) if it prices its Hong Kong IPO at the mid-point of its proposed range. Ascentage proposed to sell 12.2 million shares at $HK32.20-HK$34.20. The company refiled to list in April after letting its application lapse.

Principia, Rhythm, ProQR price follow-ons
At least three companies raised follow-ons Wednesday, with Principia BioPharma Inc. (NASDAQ:PRNB) raising the most at $210 million in a bumped-up offering. The company sold 7.5 million shares at $28, a 6% discount from Tuesday’s close of $29.91. The company had proposed to raise $125 million. Rhythm Pharmceuticals Inc. (NASDAQ:RYTM) raised $150 million in its offering of 8.1 million shares at $18.50, an 11% discount from Tuesday’s close of $20.89. ProQR Therapeutics N.V. (NASDAQ:PRQR) raised $50 million via the sale of 9.1 million shares at $5.50 a share, a 12% discount from Tuesday’s close of $6.22...